FLT3 and acute myeloid leukemia: Sorafenib’s efficacy on FLT3 alterations was also reported in a study involving six children with relapsed/refractory AML where four patients initially achieved complete remission with sorafenib, three of them experienced relapse within 14 to 37 weeks (29).